Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis.

Ethier JL, Desautels D, Templeton A, Shah PS, Amir E. · 2017

Read Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. by Ethier JL, Desautels D, Templeton A, Shah PS, Amir E. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5217326.txt.

Introduction

Josee-Lyne Ethier, Danielle Desautels, Arnoud Templeton, Prakesh S. Shah, and Eitan Amir pooled evidence on the neutrophil-to-lymphocyte ratio in breast cancer in Breast Cancer Research in 2017. The ratio comes from a standard blood count, and high values had been linked to higher death rates in several cancers. Whether that held in breast cancer, and for which patients, was less clear.

The search found fifteen studies covering 8,563 patients, with high-ratio cut-offs ranging from 1.9 to 5.0 across studies. Patients above the cut-off had clearly worse overall survival and worse disease-free survival. The pattern held in early-stage disease and in mixed early and advanced groups. The survival link was stronger for disease-free survival in tumours lacking estrogen receptors and HER2. The authors call the ratio a cheap, easy prognostic marker worth adding to risk models.

Catalog record

CREATOREthier JL, Desautels D, Templeton A, Shah PS, Amir E.
YEAR2017
COLLECTIONPAPERS
FORMATTXT
FILE SIZE30 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5217326

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis By Josee-Lyne Ethier, Danielle Desautels, Arnoud Templeton, Prakesh S Shah, Eitan Amir Published in: Breast Cancer Research : BCR DOI: 10.1186/s13058-016-0794-1 ABSTRACT Abstract Background The presence of a high neutrophil-to-lymphocyte ratio (NLR) has been associated with increased mortality in several malignancies. Here, we quantify the effect of NLR on survival in patients with breast cancer, and examine the effect of clinicopathologic factors on its prognostic value. Methods A systematic search of electronic databases was conducted to identify publications exploring the association of blood NLR (measured pre treatment) and overall survival (OS) and disease-free survival (DFS) among patients with breast cancer. Data from studies reporting a hazard ratio (HR) and 95% confidence interval (CI) or a P value were pooled in a meta-analysis. Pooled HRs were computed and weighted using generic inverse variance. Meta-regression was performed to evaluate the influence of clinicopathologic factors such as age, disease stage, tumor grade, nodal involvement, receptor status, and NLR cutoff on the HR for OS and DFS. All statistical tests were two-sided. Results Fifteen studies comprising a total of 8563 patients were included. The studies used different cutoff values to classify high NLR (range 1.9–5.0). The median cutoff value for high NLR used in these studies was 3.0 amongst 13 studies reporting a HR for OS, and 2.5 in 10 studies reporting DFS outcomes. NLR greater than the cutoff value was associated with worse OS (HR 2.56, 95% CI = 1.96–3.35; P < 0.001) and DFS (HR 1.74, 95% CI = 1.47–2.07; P < 0.001). This association was similar in studies including only early-stage disease and those comprising patients with both early-stage and metastatic disease. Estrogen receptor (ER) and HER-2 appeared to modify the effect of NLR on DFS, because NLR had greater prognostic value for DFS in ER-negative and HER2-negative breast cancer. No subgroup showed an influence on the association between NLR and OS. Conclusions High NLR is associated with an adverse OS and DFS in patients with breast cancer with a greater effect on disease-specific outcome in ER and HER2-negative disease. NLR is an easily accessible prognostic marker, and its addition to established risk prediction models warrants further investigation. Keywords: Breast cancer, Neutrophil-to-lymphocyte ratio, Prognosis, Disease-free survival, Overall survival, Meta-analysis, Systematic review BACKGROUND The short-term and long-term prognosis of breast cancer depends on patient and tumor factors such as age, disease stage, and biological factors such as grade and receptor status. However, the behavior of breast cancer is unpredictable, with markedly different clinical outcomes seen even amongst patients with similar classical prognostic factors [1]. Inflammatory cells and mediators in the tumor microenvironment are thought to play an important role in cancer progression, and may account for some of this variability [2]. The presence of an elevated peripheral neutrophil-to-lymphocyte (NLR) ratio, an indicator of systemic inflammation, has been recognized as a poor prognostic factor in various cancers [3]. In a previous meta-analysis of 100 studies of patients with unselected solid tumors, increased NLR was associated with decreased overall survival (OS) (hazard ratio (HR) 1.81; 95% confidence interval (CI) = 1.67–1.97; P < 0.001) [4]. This effect was observed in all disease sites, subgroups, and stages. However, this study was not specific to breast cancer, and did not examine the impact of prognostic factors such as estrogen receptor (ER) or progesterone receptor (PR) status, HER2 status, disease stage, or menopausal status. The aim of this study was to quantify the effect of peripheral blood NLR on OS and disease-free survival (DFS) in adult women with invasive breast cancer. We also examined the effect of clinicopathologic factors on the prognostic value of NLR. METHODS Data sources and searches This analysis was reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [5]. The search strategy developed by Templeton et al. [4] was used with the addition of “breast neoplasms” and synonymous breast cancer-specific terms. An electronic search of the following databases was performed: Medline (host: OVID), Medline in Process, Medline Epub Ahead of Print (host: OVID), EMBASE (host: OVID), and Cochrane Database of Systematic Reviews. All databases were searched from January 2013 to April 2016, supplementing the initial systematic review that searched databases until different time points in 2013. Citation lists of retrieved articles were screened manually to ensure sensitivity of the search strategy. The full search strategy is described in Table 3 in Appendix 1. Study selection In order to reduce clinical heterogeneity, the following eligibility criteria were utilized: studies of adult women with breast cancer reporting on the prognostic impact of the peripheral blood NLR, where NLR was treated as a categorical variable; NLR collected prior to all treatment (surgery and/or systemic therapy); reporting of a multivariable HR for OS, and/or DFS or progression-free survival (PFS), and corresponding 95% CI and/or P value; available as a full-text publication; clinical trials, cohort studies, or case–control studies; and English-language publication. Case reports, conference proceedings, and letters to editors were excluded. Corresponding authors were contacted to clarify missing or ambiguous data. When multiple publications or data analyses were available from the same dataset and if clarification on potentially duplicate data could not be obtained, the study reporting the larger number of patients was retained and other studies were excluded. Studies only presenting data in graphic form without reporting a numerical value for HR were excluded. All titles identified by the search were evaluated, and all potentially relevant publications were retrieved in full. Two reviewers (JE and DD) independently reviewed full articles for eligibility based on inclusion criteria and data extraction, and disagreements were resolved by consensus. Three relevant articles identified in the previous systematic review were also included [4]. Data extraction The following details were extracted from included studies using predesigned data abstraction forms: name of first author, year of publication, journal, number of patients included in analysis, median age, disease stage (nonmetastatic, metastatic, mixed (nonmetastatic and metastatic)), collection of data (prospective, retrospective), cutoff value used to define high NLR, number of patients with each breast cancer subtype, number of premenopausal and postmenopausal patients, and HRs and associated 95% CIs for OS, PFS, or DFS. Where more than one multivariable model was reported, HRs were extracted from models including the most participants. Risk of bias assessment Validity of included studies was assessed by two independent reviewers (J-LE and DD) using the Quality in Prognostic Studies (QUIPS) tool as described previously [6]. The QUIPS tool comprises 30 questions categorized into six domains (study participation, study attrition, prognostic factor measurement, outcome measurement, study confounding, and statistical analysis and reporting). Studies were rated according to each domain as being at low, moderate, or high risk of bias, based on the likelihood that they might alter the relationship between the prognostic factor and outcome. Statistical analyses Extracted data were pooled using RevMan 5.3 analysis software (Cochrane Collaboration, Copenhagen, Denmark). A meta-analysis was conducted for all included studies for each of the endpoints of interest if appropriate when clinical heterogeneity was minimal. The primary outcome of interest was OS, and intermediate endpoints such as PFS and/or DFS were secondary outcomes. Estimates for HRs were pooled and weighted by generic inverse variance, and were

Read the complete text